Weight-Loss Medications Linked to Reduced Risk of Numerous Health Conditions
Research indicates potential broader health benefits of GLP-1 receptor agonists for individuals with diabetes.
A recent study has revealed that individuals with diabetes who use GLP-1 receptor agonists (GLP-1RAs) such as liraglutide, semaglutide, and tirzepatide, found in medications like Saxenda, Wegovy, and Mounjaro, have a reduced risk of developing 42 different health conditions, including dementia, psychotic disorders, and infections.
This discovery broadens the potential applications for these medications beyond diabetes management.
Published in the journal Nature Medicine, the comprehensive research utilized data from the US Department of Veterans Affairs and studied health outcomes among 215,970 diabetic individuals receiving GLP-1RAs compared to 1,203,097 individuals undergoing usual care with other blood-sugar-lowering medications.
Over a median follow-up period of about 3.5 years, results showed GLP-1RAs were associated with a lower risk of conditions such as clotting disorders, chronic kidney disease, opioid-use disorders, bulimia, Alzheimer's disease, and bacterial infections, with risk reductions ranging between 10% to 19%.
Despite the benefits, the use of GLP-1RAs was also linked to an increased risk of 19 conditions, including abdominal pain, nausea, vomiting, low blood pressure, and kidney stones.
Notably, while aiding weight loss, these medications paradoxically heightened the risk of arthritis.
Dr. Ziyad Al-Aly, a co-author from Washington University in St. Louis, hypothesized this could relate to decreased muscle mass and deconditioning that accompanies rapid weight loss.
The researchers suggest the health benefits observed in diabetic patients may extend to other individuals, such as those dealing with obesity.
However, Dr. Al-Aly cautioned that individuals without obesity might not experience the full range of benefits.
The findings underscore the potential of GLP-1RAs to shed light on disease mechanisms and inform future treatment pathways.
External experts, such as Prof. Naveed Sattar from the University of Glasgow, emphasize the need for further randomized trials to validate these associations and understand the net benefits and safety of these medications.
As the body of research on GLP-1RAs expands, insights into their broader use and indications continue to develop.
This discovery broadens the potential applications for these medications beyond diabetes management.
Published in the journal Nature Medicine, the comprehensive research utilized data from the US Department of Veterans Affairs and studied health outcomes among 215,970 diabetic individuals receiving GLP-1RAs compared to 1,203,097 individuals undergoing usual care with other blood-sugar-lowering medications.
Over a median follow-up period of about 3.5 years, results showed GLP-1RAs were associated with a lower risk of conditions such as clotting disorders, chronic kidney disease, opioid-use disorders, bulimia, Alzheimer's disease, and bacterial infections, with risk reductions ranging between 10% to 19%.
Despite the benefits, the use of GLP-1RAs was also linked to an increased risk of 19 conditions, including abdominal pain, nausea, vomiting, low blood pressure, and kidney stones.
Notably, while aiding weight loss, these medications paradoxically heightened the risk of arthritis.
Dr. Ziyad Al-Aly, a co-author from Washington University in St. Louis, hypothesized this could relate to decreased muscle mass and deconditioning that accompanies rapid weight loss.
The researchers suggest the health benefits observed in diabetic patients may extend to other individuals, such as those dealing with obesity.
However, Dr. Al-Aly cautioned that individuals without obesity might not experience the full range of benefits.
The findings underscore the potential of GLP-1RAs to shed light on disease mechanisms and inform future treatment pathways.
External experts, such as Prof. Naveed Sattar from the University of Glasgow, emphasize the need for further randomized trials to validate these associations and understand the net benefits and safety of these medications.
As the body of research on GLP-1RAs expands, insights into their broader use and indications continue to develop.
